Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co accepts USD 670m Medicaid charge

Merck & Co accepts a USD 670m charge to settle legal disputes with a number of US states over alleged overcharging for the provision of some of its drugs to Medicaid

US-based Merck & Co has accepted a USD 670m charge to settle legal disputes with a number of US states over alleged overcharging for the provision of some of its drugs to Medicaid.

Vioxx (rofecoxib) litigation costs and the Medicaid charge are forecast to trigger a USD 3.6bn reduction in Merck & Co's net earnings for FY07. The impact of the same items in 2008, however, is expected to result in a positive contribution to net earnings of USD 1.5bn.

Merck & Co's FY07 and FY08 forecasts reveal that most of the serious long-term litigation threats to the company are nearing resolution and their impact has been included.

Generics competition will undermine Merck & Co's top-line growth at a time that immediate litigation threats are finally put aside. However, the company says it will see sustained growth from cervical cancer vaccine Gardasil, diabetes treatment Januvia (sitagliptin) and Asthma drug Singulair (montelukast).

Savings from restructuring are also expected to boost the bottom line. Merck & Co is targeting pre-tax savings of USD 4.5-5bn from 2006 through 2010, of which USD 2bn will be through the implementation of a manufacturing supply strategy.

The company will meet its target of cutting 7,000 jobs by the end of 2008. It already axed 6,000 positions by the end of September 2007.

The savings and projected sales growth should enable Merck & Co to return its gross margin, starting in 2008, to levels consistent with those seen prior to the loss of US patent exclusivity for Zocor (simvastatin).

5th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics